Search Press releases Keywords From To 22 Mar 2024 UCB receives positive CHMP opinion for BIMZELX[®]▼(bimekizumab) for the treatment of adults with moderate to severe hidradenitis suppurativa Read More 15 Mar 2024 UCB announces changes on Board of Directors Read More 13 Mar 2024 UCB successfully completes institutional Eurobond issue Read More 9 Mar 2024 First presentation of four-year BIMZELX[®](bimekizumab-bkzx) data showed long-term maintenance of complete skin clearance in moderate to severe plaque psoriasis Read More 8 Mar 2024 Bimekizumab 48-week Phase 3 analyses in moderate to severe hidradenitis suppurativa showed sustained improvements in skin pain and draining tunnel count Read More 4 Mar 2024 UCB announces strategic investment in IMIDomics, Inc to advance breakthrough solutions for immune-mediated inflammatory diseases Read More Pagination First page Previous page Previous … Page 17 Page 18 Page 19 Page 20 Current page 21 Page 22 Page 23 Page 24 Page 25 … Page 21 of 70 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
